TG4001

Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201019 TG4001+avelumab SITC - EN

By nh|2020-10-16T16:20:03+02:00October 19th, 2020|Press release, TG4001, TG4001|Comments Off

Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers

CP TG4001+avelumab EN - Vdef-

By nh|2020-07-22T16:30:04+02:00July 22nd, 2020|Press release, TG4001, TG4001|Comments Off

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

20190930 PR TG4001 ESMO EN

By nh|2019-11-05T09:54:59+01:00September 30th, 2019|Press release, TG4001, TG4001|Comments Off

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al. ESMO 2019 Download the poster [...]

By Lucie Larguier|2020-07-22T14:04:14+02:00September 30th, 2019|Publication, TG4001, TG4001|Comments Off

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane M. Harper, et al. Gynecologic Oncology, April 2019 - [...]

By nh|2020-07-22T14:05:49+02:00April 18th, 2019|Publication, TG4001, TG4001|Comments Off